Related Experiment Video

Updated: Oct 23, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

701

Targeting MDSC for Immune-Checkpoint Blockade in Cancer Immunotherapy: Current Progress and New Prospects

Tianhang Li1, Tianyao Liu1, Wenjie Zhu1

  • 1Department of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Institute of Urology, Nanjing University, Nanjing, 210008, People's Republic of China.

Clinical Medicine Insights. Oncology
|August 19, 2021
PubMed

Insights

Immune-checkpoint blockade (ICB) shows promise in cancer therapy but faces challenges. Targeting myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment may overcome resistance and improve ICB efficacy.

Area of Science:

  • Immunology
  • Oncology
  • Cancer Research

Background:

  • Immune-checkpoint blockade (ICB) is a promising cancer therapy.
  • Challenges like drug resistance and patient selection limit ICB efficacy.
  • The tumor microenvironment (TME) significantly influences ICB response.

Purpose of the Study:

  • To review the role of myeloid-derived suppressor cells (MDSCs) in cancer.
  • To focus on MDSC's negative impact on ICB therapy.
  • To discuss MDSC-targeted strategies for enhancing ICB efficacy.

Main Methods:

  • Literature review of MDSC functions in cancer.
  • Analysis of MDSC's role in ICB resistance.
  • Exploration of therapeutic strategies targeting MDSCs.

Main Results:

  • MDSCs are major immune suppressors in the TME.
  • MDSCs contribute to resistance against ICB therapy.
  • Targeting MDSCs can potentially overcome ICB limitations.

Conclusions:

  • Understanding MDSC biology is crucial for improving ICB.
  • MDSC-targeted interventions offer a strategy to enhance anti-cancer immunity.
  • Optimizing ICB therapy requires addressing MDSC-mediated immunosuppression.
Keywords:
ICBMyeloid-derived suppressor cellsPD-(L) 1TMEimmune escape

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

843
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.9K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
773
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K